Trial Profile

A Phase 3 Study to Evaluate Endoxifen in a Window of Opportunity Setting in Breast Cancer Patients

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 04 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Endoxifen (Primary)
Indications Early breast cancer
Focus Registrational; Therapeutic Use
Sponsors Atossa Therapeutics

Most Recent Events

30 Apr 2025 Trial design presented at the 116th Annual Meeting of the American Association for Cancer Research.
28 Jun 2023 According to an Atossa Therapeutics media release, data from EVANGELINE and I-SPY 2 clinical trial will inform conversations with the FDA and planned Phase 3 protocol.
11 May 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com